BCG045 / Biocytogen - LARVOL DELTA

BCG045: A first-in-class bispecific ADC targeting TROP2 and MUC1 demonstrates promising tumor efficacy and potentially reduced toxicity in preclinical studies (AACR 2026) - "When conjugated with a TOP1 inhibitor (TOP1i) linker-payload, designated as BLD1102, to form BCG045, the bispecific ADC displayed potent efficacy in various patient-derived xenograft (PDX) models.BCG045 outperformed the benchmark ADCs in certain models, indicating its enhanced therapeutic potential. Overall, the data suggest that BCG045 could be a promising new treatment option for multiple tumors, offering improved efficacy and safety."

ADC • Bispecific • Preclinical • Oncology • Solid Tumor • MUC1 • TACSTD2 • TOP1